The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde

X–linked adrenoleukodystrophy (X–ALD) is the most common peroxisomal enzyme deficiency disorder, characterized by inborn mutations in the ABCD1 gene, an ATP–binding cassette (ABC) half–transporter. The ABCD1 gene encodes the adrenoleukodystrophy protein (ALDP), the transporter for the very–long–chai...

Full description

Bibliographic Details
Main Author: Van der Linde, Wilhelmina Johanna
Published: North-West University 2011
Subjects:
Online Access:http://hdl.handle.net/10394/4916
id ndltd-netd.ac.za-oai-union.ndltd.org-nwu-oai-dspace.nwu.ac.za-10394-4916
record_format oai_dc
spelling ndltd-netd.ac.za-oai-union.ndltd.org-nwu-oai-dspace.nwu.ac.za-10394-49162014-04-16T03:53:11ZThe metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der LindeVan der Linde, Wilhelmina JohannaX-gekoppelde adrenoleukodistrofië (X-ALD)4-PBBLKVPeroksisoom proliferasieX-linked adrenoleukodystrophy (X-ALD)Very-long-chain fatty acids (VLCFA)Reactive oxygen species (ROS)Lipid peroxidation (LP)Peroxisome proliferationX–linked adrenoleukodystrophy (X–ALD) is the most common peroxisomal enzyme deficiency disorder, characterized by inborn mutations in the ABCD1 gene, an ATP–binding cassette (ABC) half–transporter. The ABCD1 gene encodes the adrenoleukodystrophy protein (ALDP), the transporter for the very–long–chain fatty acids (VLCFA; C > 22:0) from the cytosol into the peroxisomes to enter the peroxisomal B–oxidation pathway. The diagnostic disease marker is the elevated levels of VLCFAs which accumulate in different tissues and body fluids, leading to inflammatory demyelination, neuro–deterioration and adrenocortical insufficiency. At present, there is no satisfactory therapy for X–ALD available. However, another peroxisomal ABC half–transporter, ALDRP can compensate for the functional loss of ALDP and is encoded by the ABCD2 gene. This prompted a new approach to treatment strategies. Phenylbutyric acid (PBA) over–expresses the ABCD2 gene, leading to an increased expression of ALDRP and PBA decreases VLCFA levels by increasing peroxisomal B–oxidation. This study had a dual aim: to determine the antioxidant capacity of PBA and to verify known and identify new metabolites of PBA. In vitro, HeLa cells were cultivated and treated with 0.5 mM, 1 mM, 2 mM and 5 mM PBA for 48 hours. The ROS, lipid peroxidation, apoptosis and cell viability were determined using fluorescein–based flow cytometry. Images were taken to visualize the peroxisome proliferation. In vivo, a vervet monkey was given a single dose of 130 mg/kg PBA. Blood was collected before treatment and 15 minutes, 30 minutes, 1, 2 and 3 hours after treatment. ROS, apoptosis and lipid peroxidation were determined by fluorescein–based flow cytometry. Urine was collected before treatment and 15 minutes, 30 minutes, 1, 2, 3, 7 and 24 hours after PBA treatment. A standardised method, employing gas chromatography–mass spectrometry (GC/MS), was used to analyse the organic acids in the urine and fatty acids in the blood. In vitro results showed decreased levels of ROS and lipid peroxidation with increased concentrations of PBA. PBA showed a protective effect towards the HeLa cells with reduced apoptosis and a high number of viable cells. In vivo levels of ROS en lipid peroxidation decreased over time of treatment with PBA. The fluorescence microscope images confirmed an increased number of peroxisomes after PBA treatment. The short term effect of PBA showed an initial, but small decrease in the levels of the fatty acids, suggesting induction over a longer period rather than activation of peroxisomal B–oxidation. New metabolites of phenylbutyrate were identified in the urine of a vervet monkey. These new metabolites originated from monooxygenase, N–phenylacetyl–glutamine synthases and B–oxidation byproducts. Recently discovered metabolites in humans and rats were also verified and confirmed in the vervet monkey. We therefore propose that treatment with PBA, on account of its beneficial effects of restoring VLCFA levels and reducing oxidative stress, could be considered a novel approach for the treatment of X–ALD.Thesis (M.Sc. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2011.North-West University2011-10-05T10:20:57Z2011-10-05T10:20:57Z2010Thesishttp://hdl.handle.net/10394/4916
collection NDLTD
sources NDLTD
topic X-gekoppelde adrenoleukodistrofië (X-ALD)
4-PB
BLKV
Peroksisoom proliferasie
X-linked adrenoleukodystrophy (X-ALD)
Very-long-chain fatty acids (VLCFA)
Reactive oxygen species (ROS)
Lipid peroxidation (LP)
Peroxisome proliferation
spellingShingle X-gekoppelde adrenoleukodistrofië (X-ALD)
4-PB
BLKV
Peroksisoom proliferasie
X-linked adrenoleukodystrophy (X-ALD)
Very-long-chain fatty acids (VLCFA)
Reactive oxygen species (ROS)
Lipid peroxidation (LP)
Peroxisome proliferation
Van der Linde, Wilhelmina Johanna
The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
description X–linked adrenoleukodystrophy (X–ALD) is the most common peroxisomal enzyme deficiency disorder, characterized by inborn mutations in the ABCD1 gene, an ATP–binding cassette (ABC) half–transporter. The ABCD1 gene encodes the adrenoleukodystrophy protein (ALDP), the transporter for the very–long–chain fatty acids (VLCFA; C > 22:0) from the cytosol into the peroxisomes to enter the peroxisomal B–oxidation pathway. The diagnostic disease marker is the elevated levels of VLCFAs which accumulate in different tissues and body fluids, leading to inflammatory demyelination, neuro–deterioration and adrenocortical insufficiency. At present, there is no satisfactory therapy for X–ALD available. However, another peroxisomal ABC half–transporter, ALDRP can compensate for the functional loss of ALDP and is encoded by the ABCD2 gene. This prompted a new approach to treatment strategies. Phenylbutyric acid (PBA) over–expresses the ABCD2 gene, leading to an increased expression of ALDRP and PBA decreases VLCFA levels by increasing peroxisomal B–oxidation. This study had a dual aim: to determine the antioxidant capacity of PBA and to verify known and identify new metabolites of PBA. In vitro, HeLa cells were cultivated and treated with 0.5 mM, 1 mM, 2 mM and 5 mM PBA for 48 hours. The ROS, lipid peroxidation, apoptosis and cell viability were determined using fluorescein–based flow cytometry. Images were taken to visualize the peroxisome proliferation. In vivo, a vervet monkey was given a single dose of 130 mg/kg PBA. Blood was collected before treatment and 15 minutes, 30 minutes, 1, 2 and 3 hours after treatment. ROS, apoptosis and lipid peroxidation were determined by fluorescein–based flow cytometry. Urine was collected before treatment and 15 minutes, 30 minutes, 1, 2, 3, 7 and 24 hours after PBA treatment. A standardised method, employing gas chromatography–mass spectrometry (GC/MS), was used to analyse the organic acids in the urine and fatty acids in the blood. In vitro results showed decreased levels of ROS and lipid peroxidation with increased concentrations of PBA. PBA showed a protective effect towards the HeLa cells with reduced apoptosis and a high number of viable cells. In vivo levels of ROS en lipid peroxidation decreased over time of treatment with PBA. The fluorescence microscope images confirmed an increased number of peroxisomes after PBA treatment. The short term effect of PBA showed an initial, but small decrease in the levels of the fatty acids, suggesting induction over a longer period rather than activation of peroxisomal B–oxidation. New metabolites of phenylbutyrate were identified in the urine of a vervet monkey. These new metabolites originated from monooxygenase, N–phenylacetyl–glutamine synthases and B–oxidation byproducts. Recently discovered metabolites in humans and rats were also verified and confirmed in the vervet monkey. We therefore propose that treatment with PBA, on account of its beneficial effects of restoring VLCFA levels and reducing oxidative stress, could be considered a novel approach for the treatment of X–ALD. === Thesis (M.Sc. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2011.
author Van der Linde, Wilhelmina Johanna
author_facet Van der Linde, Wilhelmina Johanna
author_sort Van der Linde, Wilhelmina Johanna
title The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
title_short The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
title_full The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
title_fullStr The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
title_full_unstemmed The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / Wilhelmina Johanna van der Linde
title_sort metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys / wilhelmina johanna van der linde
publisher North-West University
publishDate 2011
url http://hdl.handle.net/10394/4916
work_keys_str_mv AT vanderlindewilhelminajohanna themetabolicprofileofphenylbutyricacidanditsantioxidantcapacityinvervetmonkeyswilhelminajohannavanderlinde
AT vanderlindewilhelminajohanna metabolicprofileofphenylbutyricacidanditsantioxidantcapacityinvervetmonkeyswilhelminajohannavanderlinde
_version_ 1716663941191434240